NewLeaf Symbiotics
Science-based company doing cutting-edge research and product development, using a naturally occurring family of beneficial plant bacteria.
Launch date
Employees
Market cap
-
Enterprise valuation
€164—245m (Dealroom.co estimates Dec 2023.)
Olivette Missouri (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$30.0m | Series C | ||
* | $20.0m | Series D | |
$2.0m Valuation: $150m | Series D | ||
N/A | $10.0m | Convertible | |
* | $45.0m | Series D | |
Total Funding | €119m |
Related Content
Recent News about NewLeaf Symbiotics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by NewLeaf Symbiotics
EditACQUISITION by NewLeaf Symbiotics Dec 2013